BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 8384496)

  • 1. Binding of urinary protein C inhibitor to fibrin(ogen) and its binding mechanism.
    Hayashi S; Yamada K
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):153-8. PubMed ID: 8384496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the beta-chain hole of fibrinogen with synthetic peptides that differ at their amino termini.
    Doolittle RF; Pandi L
    Biochemistry; 2007 Sep; 46(35):10033-8. PubMed ID: 17688324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Plasminogen-binding centers of molecules of fibrinogen, fibrin and products of their proteolysis].
    Grinenko TV; Tret'iachenko VG; Kudinov SA; Medved' LV
    Biokhimiia; 1987 Oct; 52(10):1732-9. PubMed ID: 3427134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinogen catabolism within the procoagulant VX-2 tumor of rabbit lung in vivo: Effluxing fibrin(ogen) fragments contain antiangiogenic activity.
    Hatton MW; Southward SM; Legault KJ; Ross BL; Clarke BJ; Bajzar L; Blajchman MA; Singh G; Richardson M
    J Lab Clin Med; 2004 Apr; 143(4):241-54. PubMed ID: 15085083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary protein C inhibitor binding region in the B beta-chain of human fibrinogen.
    Hayashi S
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):921-6. PubMed ID: 8148485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of fibrin(ogen) with heparin: further characterization and localization of the heparin-binding site.
    Yakovlev S; Gorlatov S; Ingham K; Medved L
    Biochemistry; 2003 Jul; 42(25):7709-16. PubMed ID: 12820880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots.
    Sangrar W; Koschinsky ML
    Biochem Cell Biol; 2000; 78(4):519-25. PubMed ID: 11012092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The fibrinogenolytic activity of purified tryptase from human lung mast cells.
    Schwartz LB; Bradford TR; Littman BH; Wintroub BU
    J Immunol; 1985 Oct; 135(4):2762-7. PubMed ID: 3161948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): hydrolysis of the gamma Gly 404-Ala 405 peptide bond.
    Bini A; Itoh Y; Kudryk BJ; Nagase H
    Biochemistry; 1996 Oct; 35(40):13056-63. PubMed ID: 8855941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of fibrinolysis in chronic subdural hematoma].
    Trappe A; Hafter R; Wendt P; Graeff H; Blümel G
    Neurochirurgia (Stuttg); 1986 May; 29(3):78-82. PubMed ID: 3724938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The receptor for the globular "heads" of C1q, gC1q-R, binds to fibrinogen/fibrin and impairs its polymerization.
    Lu PD; Galanakis DK; Ghebrehiwet B; Peerschke EI
    Clin Immunol; 1999 Mar; 90(3):360-7. PubMed ID: 10075865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Location of plasminogen-binding sites in human fibrin(ogen).
    Váradi A; Patthy L
    Biochemistry; 1983 May; 22(10):2440-6. PubMed ID: 6222763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catabolism of purified rat fibrin(ogen) plasmin degradation products in rats.
    Nieuwenhuizen W; Emeis JJ; Vermond A
    Thromb Haemost; 1982 Aug; 48(1):59-61. PubMed ID: 7135343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinogen and fibrin polymerization: appraisal of the binding events that accompany fibrin generation and fibrin clot assembly.
    Mosesson MW
    Blood Coagul Fibrinolysis; 1997 Jul; 8(5):257-67. PubMed ID: 9282789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fibrin (ogen) Split products of nephropathies].
    Anger H
    Urologe A; 1975 Jan; 14(1):20-4. PubMed ID: 234643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational changes in fragments D and double-D from human fibrin(ogen) upon binding the peptide ligand Gly-His-Arg-Pro-amide.
    Everse SJ; Spraggon G; Veerapandian L; Doolittle RF
    Biochemistry; 1999 Mar; 38(10):2941-6. PubMed ID: 10074346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that catalytically-inactivated thrombin forms non-covalently linked dimers that bridge between fibrin/fibrinogen fibers and enhance fibrin polymerization.
    Mosesson MW; Hernandez I; Siebenlist KR
    Biophys Chem; 2004 Jul; 110(1-2):93-100. PubMed ID: 15223147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure and biological features of fibrinogen and fibrin.
    Mosesson MW; Siebenlist KR; Meh DA
    Ann N Y Acad Sci; 2001; 936():11-30. PubMed ID: 11460466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological behavior of higher molecular weight products of fibrinolysis.
    Chang ML; Bang NU
    J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: pro-inflammatory effect on atherosclerosis.
    Guo F; Liu J; Wang C; Liu N; Lu P
    Biochem Biophys Res Commun; 2009 Dec; 390(3):942-6. PubMed ID: 19852936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.